<?xml version="1.0" encoding="UTF-8"?>
<ref id="B145-jcm-09-02084">
 <label>145.</label>
 <element-citation publication-type="journal">
  <person-group person-group-type="author">
   <name>
    <surname>King</surname>
    <given-names>A.</given-names>
   </name>
   <name>
    <surname>Vail</surname>
    <given-names>A.</given-names>
   </name>
   <name>
    <surname>Oâ€™Leary</surname>
    <given-names>C.</given-names>
   </name>
   <name>
    <surname>Hannan</surname>
    <given-names>C.</given-names>
   </name>
   <name>
    <surname>Brough</surname>
    <given-names>D.</given-names>
   </name>
   <name>
    <surname>Patel</surname>
    <given-names>H.</given-names>
   </name>
   <name>
    <surname>Galea</surname>
    <given-names>J.</given-names>
   </name>
   <name>
    <surname>Ogungbenro</surname>
    <given-names>K.</given-names>
   </name>
   <name>
    <surname>Wright</surname>
    <given-names>M.</given-names>
   </name>
   <name>
    <surname>Pathmanaban</surname>
    <given-names>O.</given-names>
   </name>
   <etal/>
  </person-group>
  <article-title>Anakinra in COVID-19: Important Considerations for Clinical Trials</article-title>
  <source>Lancet Rheumatol.</source>
  <year>2020</year>
  <volume>2</volume>
  <fpage>20</fpage>
  <lpage>22</lpage>
  <pub-id pub-id-type="doi">10.1016/S2665-9913(20)30160-0</pub-id>
 </element-citation>
</ref>
